Explore UAB

ConferenceJune 2023 brings with it many endocrinology and diabetes conference opportunities. Notably, the Endocrine Society meeting, ENDO 2023, and the American Diabetes Association (ADA) 83rd Scientific Session.

ENDO 2023 is June 15-18, 2023, in Chicago, Illinois. This year, the Endocrine Society expects over 7,000 attendees, nearly 2,000 abstracts and over 200 other sessions. Of those presenting at ENDO 2023, Division of Endocrinology, Diabetes, and Metabolism Fellow Fernando Bril, M.D., received an outstanding abstract award. See the list of those presenting below.

  • Fernando Bril: “Assessment of NAFLD Burden in an Employee Wellness Program Among Non-Obese Patients Without Evident Metabolic Abnormalities” and “Chronic Free Fatty Acid Elevation Is Associated with an Overcompensatory Increase in Hepatic Mitochondrial Function in Patients with Overweight or Obesity”
  • Sebastian Campana: “Tacrolimus Levels and Kidney Function in Kidney Transplanted (KT) Patients with Diabetes on Glucagon Like-1 Receptor Agonists (GLP1-RA)”

The ADA 83rd Scientific Session, on June 23-26 in San Diego, CA, will gather leading physicians, scientists, and health care professionals from around the world to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. See the list of those presenting below.

  • Abdulaziz Almutairi: "Macrophage-derived Proinflammatory Lipids Contribute To the Development of Type 1 Diabetes."
  • Fernando Bril: “Screening for Liver Fibrosis in Diabetes—Assessing the Performance of Current Recommendations in a Large Unselected Population”
  • Tanya Hans Pierre: “The Rnf20 Ubiquitin Ligase Is Required for Beta-Cell Identity and Function.”
Tanya will discuss how loss of this epigenetic modifier in adult beta-cells causes a disruption of glucose homeostasis and beta-cell gene expression. The goal of this project is to enrich our understanding of the transcriptional mechanisms regulating beta-cell maintenance.

  • SeongHo Jo: "Anti-diabetic TIX100 improves NAFLD/NASH in mice with and without diabetes and obesity"
  • Mostafizur Rahman (Haifa A, Bhatnagar S): "The Beta-Cell Specific Deletion of Complement 1q-Like-3 Secreted Protein Improves Beta-Cell Function and Glucose Homeostasis"
  • Tayleur White: "Reduced iPLA2b Expression in T-Lymphocytes Decreases Pro-Inflammatory Eicosanoids Production and Cytokine Secretion Delaying Type I Diabetes Development in NOD Mice"
  • Guanlan Xu: “Verapamil prevents decline of IGF-1 in subjects with T1D.”
The team of researchers note, “Our results reveal yet another previously unappreciated pathway affected by verapamil that may contribute to the beneficial effects observed with this treatment in the context of T1D.”

In addition to several presentations by faculty and trainees, the UCDC will also be represented at the symposium level. Director of the UAB Comprehensive Diabetes Center and Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research Anath Shalev, M.D., was invited to present at the ADA Symposium "Major Advances and Discoveries in Diabetes—The Year in Review" as a translational science representative. Shalev notes in her ADA presenter profile that she will discuss "opportunities and challenges of translational research in diabetes and provide some recent examples of successful advances made pertaining especially to the treatment of Type 1 diabetes."

Be sure to add the above talks and poster presentations to your program scheduler to support fellow colleagues. If you have an upcoming presentation you would like to share, email diabetescomm@uabmc.edu.